Continued Sabatolimab Treatment for Cancer
Trial Summary
What is the purpose of this trial?
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
Do I have to stop taking my current medications for this trial?
The protocol does not specify whether you need to stop taking your current medications. However, since this trial is for participants already on sabatolimab, it seems likely that you can continue your current medications unless otherwise advised by the study team.
What data supports the idea that Continued Sabatolimab Treatment for Cancer is an effective treatment?
The available research shows that Sabatolimab, when used with other treatments, has shown promise in treating certain types of cancer. For example, in a study involving patients with higher-risk myelodysplastic syndromes, Sabatolimab combined with another drug improved outcomes compared to a placebo. This suggests that Sabatolimab can be effective in enhancing the body's immune response to fight cancer. Additionally, it has been tested in combination with another antibody in patients with advanced solid tumors, indicating its potential in treating various cancer types.12345
What safety data is available for sabatolimab treatment?
Sabatolimab has been evaluated in several clinical trials for its safety and efficacy. A Phase I/Ib trial assessed sabatolimab alone and in combination with spartalizumab in patients with advanced solid tumors, focusing on safety and efficacy. Additionally, a Phase 2 trial (STIMULUS-MDS1) investigated the safety of sabatolimab combined with hypomethylating agents in patients with higher-risk myelodysplastic syndromes. These studies provide initial safety data for sabatolimab in different cancer types.12346
Is the drug Sabatolimab a promising treatment for cancer?
Yes, Sabatolimab is a promising drug for cancer treatment. It is an immunotherapy that targets the TIM-3 receptor, which is involved in regulating immune responses. By blocking this receptor, Sabatolimab can enhance the body's ability to fight cancer. It has shown potential in treating advanced solid tumors and blood-related cancers like acute myeloid leukemia and myelodysplastic syndromes. This drug works by boosting the immune system's attack on cancer cells, making it a valuable addition to cancer therapies.12347
Eligibility Criteria
This trial is for patients with Chronic Myelomonocytic Leukemia or Myelodysplastic Syndrome who have completed a prior Novartis-sponsored study and are still benefiting from Sabatolimab. They must be compliant with the previous study's protocol, not pregnant, willing to follow contraception guidelines, and without unresolved toxicities from Sabatolimab.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Sabatolimab (Monoclonal Antibodies)
- Spartalizumab (Monoclonal Antibodies)